18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Recruiting in Palo Alto (17 mi)

Overseen bySteven H Lin, MD, PHD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

Research Team

Steven H Lin, MD, PHD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Inclusion Criteria

I am 18 years old or older.

I can sign and understand the consent form.

I am a woman able to have children and have a recent negative pregnancy test.

See 2 more

Treatment Details

Participant Groups

1Treatment groups

Experimental Treatment

Group I: ObservationalExperimental Treatment1 Intervention

Patients receive 18F-FSPG IV and undergo a PET/CT scan. During week 3 of standard of care radiation therapy, patients receive 18F-FSPG and undergo a second PET/CT scan on study.